Similar articles for PMID: 19474123

Year	Number of Results
2006	1
2007	1
2009	4
2010	3
2011	2
2012	9
2013	9
2014	10
2015	25
2016	18
2017	15
2018	8
2019	5
2020	3
2021	3
2023	0

1

Ipilimumab-induced hypophysitis: MR imaging findings.

Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Carpenter KJ, et al. AJNR Am J Neuroradiol. 2009 Oct;30(9):1751-3. doi: 10.3174/ajnr.A1623. Epub 2009 May 27. AJNR Am J Neuroradiol. 2009. PMID: 19474123 Free PMC article.

2

Hyponatremia associated with Ipilimumab-induced hypophysitis.

Barnard ZR, Walcott BP, Kahle KT, Nahed BV, Coumans JV. Barnard ZR, et al. Med Oncol. 2012 Mar;29(1):374-7. doi: 10.1007/s12032-010-9794-7. Epub 2011 Jan 25. Med Oncol. 2012. PMID: 21264545

3

Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.

Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS, Kaiser UB. Min L, et al. Clin Cancer Res. 2015 Feb 15;21(4):749-55. doi: 10.1158/1078-0432.CCR-14-2353. Epub 2014 Dec 23. Clin Cancer Res. 2015. PMID: 25538262 Free PMC article.

4

Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.

Nallapaneni NN, Mourya R, Bhatt VR, Malhotra S, Ganti AK, Tendulkar KK. Nallapaneni NN, et al. J Natl Compr Canc Netw. 2014 Aug;12(8):1077-81. doi: 10.6004/jnccn.2014.0105. J Natl Compr Canc Netw. 2014. PMID: 25099440

5

[Ipilimumab-induced hypophysitis].

Schleder S, Schreml S, Heiss P. Schleder S, et al. Rofo. 2013 Mar;185(3):268-9. doi: 10.1055/s-0032-1325515. Epub 2012 Nov 15. Rofo. 2013. PMID: 23154861 German. No abstract available.

6

Pituitary enlargement following ipilimumab without long term endocrine dysfunction.

Nogueira E, Menon A, Dede A, Mitra I, Brock C, Larkin J, Morganstein D. Nogueira E, et al. Curr Probl Cancer. 2021 Dec;45(6):100710. doi: 10.1016/j.currproblcancer.2021.100710. Epub 2021 Feb 10. Curr Probl Cancer. 2021. PMID: 33622518

7

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA. Yang JC, et al. J Immunother. 2007 Nov-Dec;30(8):825-30. doi: 10.1097/CJI.0b013e318156e47e. J Immunother. 2007. PMID: 18049334 Free PMC article. Clinical Trial.

8

Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.

Albarel F, Gaudy C, Castinetti F, Carré T, Morange I, Conte-Devolx B, Grob JJ, Brue T. Albarel F, et al. Eur J Endocrinol. 2015 Feb;172(2):195-204. doi: 10.1530/EJE-14-0845. Epub 2014 Nov 21. Eur J Endocrinol. 2015. PMID: 25416723 Clinical Trial.

9

Ipilimumab-Induced Autoimmune Hypophysitis: Diagnostic and Management Challenges Illustrated by a Clinical Case.

Marques P, Grossman A. Marques P, et al. Acta Med Port. 2015 Nov-Dec;28(6):775-9. doi: 10.20344/amp.6541. Acta Med Port. 2015. PMID: 27265913

10

[Lymphocytic hypophysitis due to ipilimumap therapy].

Thomsen HH. Thomsen HH. Ugeskr Laeger. 2012 Jun 25;174(26):1829-30. Ugeskr Laeger. 2012. PMID: 22735122 Danish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed